A new study published in the journal of PloS One showed that although reoperative therapy with evolocumab with rosuvastatin ...

These results tout the potential of the combination as the new standard of care (SoC) for PsA patients with comorbid obesity.

Under normal conditions, cytokines aid in pathogen recognition and elimination while contributing to immune system homeostasis. When the immune system malfunctions, irregularities in cytokine ...

In a study published in Nature Immunology on January 6, a research team led by Prof. Qian Youcun from the Shanghai Institute ...

Findings underscore the risk for graded exercise in people with post-exertional malaise and point to careful activity pacing as a safer approach.

The psoriasis market is experiencing steady growth, driven by rising disease prevalence, improved diagnosis rates, and ...

Biologic vs conventional DMARDs may offer cardioprotective benefits among patients with PsA, though an increased risk for infection requires vigilance.

IDOR-1117-2520 is now in a Phase 2 proof-of-concept trial in psoriasis, with the potential to expand into additional autoimmune conditions where the CCR6-CCL20 pathway plays a pathogenic role.

The psoriasis market is experiencing steady growth, driven by rising disease prevalence, improved diagnosis rates, and greater patient access to advanced therapies. The shift from conventional ...